ROMA (RISK OF OVARIAN MALIGNANCY): Purpose, Test, Results and Clinical Importance
Ovarian health is an important part of women’s healthcare, particularly when symptoms, an ovarian mass or an abnormal finding on imaging requires further evaluation. Some ovarian conditions are benign, while others may require additional investigation to determine the likelihood of malignancy.
ROMA (RISK OF OVARIAN MALIGNANCY) is a laboratory-based risk assessment used to help estimate the likelihood of epithelial ovarian cancer in certain women who have an adnexal or ovarian mass. It combines specific blood-test results with menopausal status to generate a risk score.
It is important to understand that ROMA (RISK OF OVARIAN MALIGNANCY) does not by itself diagnose ovarian cancer. The result needs to be interpreted along with clinical examination, imaging findings, medical history and other investigations recommended by a qualified healthcare professional.
At AreYouHealthy.in, we offer diagnostic tests and health checkup packages and are a ThyroCare channel partner. Customers can check the availability of women’s health and specialised laboratory investigations based on their location.
What Is ROMA (RISK OF OVARIAN MALIGNANCY)?
ROMA (RISK OF OVARIAN MALIGNANCY) is a risk-prediction algorithm that uses blood biomarkers and menopausal status to estimate the probability that an ovarian or adnexal mass may be malignant.
The algorithm generally incorporates two tumour-associated biomarkers:
- CA-125
- HE4
The interpretation also considers whether the woman is premenopausal or postmenopausal.
The combination of these factors produces a ROMA score or risk category according to the laboratory’s validated methodology and reference thresholds.
Because ROMA (RISK OF OVARIAN MALIGNANCY) is designed for women who already have an adnexal mass requiring evaluation, it should not be considered a general population screening test for ovarian cancer.
Why Is ROMA (RISK OF OVARIAN MALIGNANCY) Done?
When an ovarian or adnexal mass is identified, doctors need to assess whether it is more likely to be benign or potentially malignant. Imaging techniques such as ultrasound provide important structural information, while laboratory biomarkers can provide additional information in selected cases.
ROMA (RISK OF OVARIAN MALIGNANCY) may help support this assessment and assist healthcare professionals in deciding how a patient should be evaluated or referred.
It may be considered when:
- An adnexal or ovarian mass has been identified
- Imaging has produced an uncertain finding
- Further risk assessment is clinically appropriate
- A gynaecologist is evaluating an ovarian mass
- Specialist referral or surgical planning requires additional information
The test should be ordered and interpreted within the appropriate clinical context.
Understanding CA-125 and HE4
To understand ROMA (RISK OF OVARIAN MALIGNANCY), it is helpful to understand the biomarkers used in the calculation.
CA-125
CA-125 is a blood biomarker that can be elevated in some women with ovarian cancer. However, an increased CA-125 level is not specific to ovarian cancer.
CA-125 may also increase in several benign or non-cancerous situations, including certain gynaecological conditions and physiological states. Therefore, an elevated CA-125 result should not automatically be interpreted as cancer.
HE4
HE4 is another biomarker used in ovarian cancer risk assessment. Like CA-125, HE4 should not be interpreted independently.
Certain non-cancerous conditions can influence HE4 levels, and interpretation may also depend on factors such as kidney function and menopausal status.
The ROMA algorithm combines these biomarkers rather than relying on either marker alone.
What Does the ROMA Score Mean?
ROMA (RISK OF OVARIAN MALIGNANCY) produces a calculated risk assessment based on the relevant laboratory measurements and menopausal status.
The report may classify the result into a lower- or higher-risk category according to the laboratory’s established cut-off values.
A higher-risk classification does not mean that ovarian cancer is definitely present. Similarly, a lower-risk classification does not completely rule out malignancy.
This distinction is essential. The result should be considered together with pelvic imaging, examination, symptoms, age, menopausal status and other relevant clinical information.
Who May Be Advised to Take ROMA Testing?
ROMA (RISK OF OVARIAN MALIGNANCY) is generally considered in women who have an adnexal or ovarian mass that requires evaluation.
A gynaecologist may recommend it when imaging or examination has identified a mass and additional risk assessment could be useful.
It is not intended as a routine test for every woman without symptoms or an ovarian/adnexal mass.
Women with persistent symptoms or concerns about ovarian health should discuss them with a gynaecologist rather than ordering a tumour-marker test independently.
Symptoms That Require Medical Evaluation
Ovarian cancer can sometimes cause nonspecific symptoms, and similar symptoms can occur with many benign conditions.
Potential symptoms can include:
- Persistent abdominal or pelvic discomfort
- Bloating or increased abdominal swelling
- Feeling full quickly while eating
- Changes in bowel habits
- Changes in urinary frequency
- Unexplained weight changes
- Persistent fatigue
- Abnormal vaginal bleeding, particularly after menopause
These symptoms do not automatically indicate ovarian cancer. However, persistent or unusual symptoms should be evaluated by a healthcare professional.
How Is ROMA Testing Performed?
ROMA (RISK OF OVARIAN MALIGNANCY) generally requires a blood sample.
The laboratory measures the relevant biomarkers and uses the patient’s menopausal status as part of the risk calculation. The result is then reported according to the laboratory’s validated algorithm and reference thresholds.
Accurate information about menopausal status is therefore important. If the laboratory or healthcare professional requests additional information, it should be provided correctly.
How to Prepare for ROMA (RISK OF OVARIAN MALIGNANCY)?
Preparation requirements depend on the current laboratory protocol and whether other tests are being performed at the same time.
Follow the instructions provided during booking. If ROMA testing is ordered alongside other blood investigations, fasting may be required because of those additional tests.
Inform your healthcare professional about relevant medicines, supplements, medical conditions and pregnancy-related circumstances when appropriate.
Do not stop prescribed medicines unless specifically advised by your doctor.
Factors That Can Influence Interpretation
ROMA results are influenced by more than the biomarker values themselves. Menopausal status is an important part of the calculation, and laboratory methodology and reference thresholds also matter.
Kidney function and certain benign conditions can affect biomarker levels. This is one reason the report should not be interpreted in isolation.
Imaging remains an important part of evaluating an ovarian or adnexal mass. Depending on the clinical situation, ultrasound, specialist examination or other investigations may be recommended.
ROMA (RISK OF OVARIAN MALIGNANCY) vs Cancer Diagnosis
ROMA (RISK OF OVARIAN MALIGNANCY) estimates risk; it does not establish a definitive cancer diagnosis.
A definitive diagnosis of ovarian cancer generally requires appropriate clinical evaluation and, when indicated, pathological assessment of tissue. The appropriate diagnostic pathway depends on the patient’s circumstances.
Therefore, a high ROMA result should not be viewed as proof of cancer, and a low result should not be interpreted as a guarantee that cancer is absent.
ROMA (RISK OF OVARIAN MALIGNANCY) in Major Indian Cities
Women searching for ROMA (RISK OF OVARIAN MALIGNANCY) testing in major Indian cities such as Delhi, Mumbai, Bengaluru, Hyderabad, Chennai, Pune, Kolkata, Ahmedabad, Jaipur, Surat, Lucknow, Gurugram, Noida, Ghaziabad and Chandigarh can check current test availability.
Home sample collection may be available for eligible diagnostic tests and locations. Collection timings, pricing, reporting timelines and serviceability can vary.
Women who have been advised to undergo the test should verify the current laboratory requirements before scheduling sample collection.
ROMA (RISK OF OVARIAN MALIGNANCY) at AreYouHealthy.in
AreYouHealthy.in provides access to diagnostic tests and health checkup packages for customers in eligible locations. As a ThyroCare channel partner, we help customers arrange a range of laboratory investigations.
If your doctor has recommended ROMA (RISK OF OVARIAN MALIGNANCY), check the current test listing for sample requirements, preparation instructions, availability and other booking information.
Because this is a specialised women’s health investigation, the result should be reviewed with the gynaecologist or healthcare professional who requested the test.
Frequently Asked Questions About ROMA (RISK OF OVARIAN MALIGNANCY)
1. What is ROMA (RISK OF OVARIAN MALIGNANCY)?
ROMA is a risk assessment algorithm that uses CA-125, HE4 and menopausal status to estimate the likelihood of malignancy in selected women with an adnexal mass.
2. Does ROMA diagnose ovarian cancer?
No. ROMA provides a risk assessment and cannot independently diagnose ovarian cancer.
3. What biomarkers are used in ROMA?
The algorithm generally uses CA-125 and HE4 along with menopausal status.
4. Is ROMA a screening test for all women?
No. It is intended for specific clinical situations, particularly evaluation of women with an adnexal mass, rather than routine screening of women without such findings.
5. What does a high ROMA score mean?
A high-risk result indicates an increased estimated likelihood of malignancy according to the applicable algorithm and cut-off. It does not prove that cancer is present.
6. What does a low ROMA score mean?
A low-risk classification indicates a lower estimated risk according to the test’s methodology. It does not completely exclude ovarian cancer.
7. Can CA-125 be high without cancer?
Yes. CA-125 can be elevated in several non-cancerous conditions, so it should not be interpreted as a cancer diagnosis by itself.
8. Why is menopausal status important?
ROMA calculations use different considerations or thresholds based on menopausal status. Accurate information about whether a woman is premenopausal or postmenopausal is therefore important.
9. Does kidney function affect ROMA-related testing?
Kidney function can influence HE4 levels and therefore may be relevant when interpreting the overall result. Your healthcare professional can assess the result in context.
10. Is fasting required for ROMA testing?
The requirement depends on the current laboratory protocol and whether other investigations are being performed. Follow the instructions provided during booking.
11. Can ROMA replace an ultrasound?
No. Imaging, particularly pelvic evaluation such as ultrasound, can provide important information about an ovarian or adnexal mass. ROMA and imaging serve different purposes.
12. What should I do if my ROMA result is high?
Discuss the result with your gynaecologist. Your doctor may consider the result alongside imaging, symptoms, medical history and other investigations to determine the appropriate next step.
Conclusion
ROMA (RISK OF OVARIAN MALIGNANCY) is a specialised laboratory risk assessment that combines CA-125, HE4 and menopausal status to estimate the likelihood of malignancy in selected women with an adnexal mass.
The test can provide additional information during the evaluation of an ovarian mass, but it should never be interpreted as a standalone cancer diagnosis. Both elevated and normal biomarker results can have multiple interpretations, making clinical context essential.
If your healthcare professional has recommended ROMA (RISK OF OVARIAN MALIGNANCY), review the current test requirements before booking and discuss the final report with your gynaecologist. Customers across eligible locations can check diagnostic testing options through AreYouHealthy.in.